Foghorn Therapeutics and Eli Lilly End SMARCA2 Cancer Program After Weak Phase 1 Results, Cut 40% of Staff

Foghorn and Lilly will not advance FHD-909 or their SMARCA2 degrader. Foghorn is cutting about 40% of staff to fund its pipeline into late 2029.